GC
IMUC

Guggenheim Capital’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Guggenheim Capital’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,984
Closed -$9K – 3097
2016
Q3 		$9K Buy
1,984
+1,038
+110% +$6.68K ﹤0.01% 2867
2016
Q2 		$9K Hold
946
– – ﹤0.01% 2854
2016
Q1 		$11K Buy
946
+467
+97% +$5.25K ﹤0.01% 2871
2015
Q4 		$7K Hold
479
– – ﹤0.01% 2958
2015
Q3 		$8K Buy
479
+60
+14% +$1.09K ﹤0.01% 2936
2015
Q2 		$8K Hold
419
– – ﹤0.01% 3026
2015
Q1 		$8K Buy
419
+108
+35% +$2.71K ﹤0.01% 3026
2014
Q4 		$9K Buy
+311
New +$8.95K ﹤0.01% 2995
2014
Q3 		– Sell
-569
Closed -$25K – 3306
2014
Q2 		$25K Sell
569
-57
-9% -$2.75K ﹤0.01% 3151
2014
Q1 		$31K Buy
626
+142
+29% +$6.94K ﹤0.01% 3193
2013
Q4 		$18K Buy
484
+29
+6% +$2.75K ﹤0.01% 3142
2013
Q3 		$47K Sell
455
-58
-11% -$6.37K ﹤0.01% 2943
2013
Q2 		$39K Buy
+513
New +$49.1K ﹤0.01% 2932

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Guggenheim Capital's IMUC Position: Q4 2016 in Review

Guggenheim Capital sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 1,984 shares — an estimated $9K sold.

Guggenheim Capital first reported a position in IMUC in Q2 2013 and held it in 13 quarters. The position peaked at $47K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Guggenheim Capital reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Guggenheim Capital sold 1,984 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $9K.
  • Guggenheim Capital first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 13 quarters.
  • Guggenheim Capital's ImmunoCellular Therapeutics, Ltd. position peaked at $47K in Q3 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.